|
1
|
Salzer L, Tenenbaum-Gavish K and Hod M:
Metabolic disorder of pregnancy (understanding pathophysiology of
diabetes and preeclampsia). Best Pract Res Clin Obstet Gynaecol.
29:328–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ding W, Cheng H, Chen F, Yan Y, Zhang M,
Zhao X, Hou D and Mi J: Adipokines are associated with hypertension
in Metabolically Healthy Obese (MHO) children and adolescents: A
prospective population-based cohort study. J Epidemiol. 28:19–26.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karelis AD, Brochu M and Rabasa-Lhoret R:
Can we identify metabolically healthy but obese individuals (MHO)?
Diabetes Metab. 30:569–572. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim TJ, Shin HY, Chang Y, Kang M, Jee J,
Choi YH, Ahn HS, Ahn SH, Son HJ and Ryu S: Metabolically healthy
obesity and the risk for subclinical atherosclerosis.
Atherosclerosis. 262:191–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moon S, Oh CM, Choi MK, Park YK, Chun S,
Choi M, Yu JM and Yoo HJ: The influence of physical activity on
risk of cardiovascular disease in people who are obese but
metabolically healthy. PLoS One. 12:e01851272017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caffarelli C, Montagnani A, Nuti R and
Gonnelli S: Bisphosphonates, atherosclerosis and vascular
calcification: Update and systematic review of clinical studies.
Clin Interv Aging. 12:1819–1828. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moore KJ and Tabas I: Macrophages in the
pathogenesis of atherosclerosis. Cell. 145:341–355. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitra R, O'Neil GL, Harding IC, Cheng MJ,
Mensah SA and Ebong EE: Glycocalyx in atherosclerosis-relevant
endothelium function and as a therapeutic target. Curr Atheroscler
Rep. 19:632017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonetti PO, Lerman LO and Lerman A:
Endothelial dysfunction: A marker of atherosclerotic risk.
Arterioscler Thromb Vasc Biol. 23:168–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bieker JJ: Krüppel-like factors: Three
fingers in many pies. J Biol Chem. 276:34355–34358. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiambaretta F, De Graeve F, Turet G,
Marceau G, Gain P, Dastugue B, Rigal D and Sapin V: Cell and tissue
specific expression of human Krüppel-like transcription factors in
human ocular surface. Mol Vis. 10:901–909. 2004.PubMed/NCBI
|
|
12
|
Wang N, Liu ZH, Ding F, Wang XQ, Zhou CN
and Wu M: Down-regulation of gut-enriched Kruppel-like factor
expression in esophageal cancer. World J Gastroenterol. 8:966–970.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y and Cai L: Does krüppel like factor
15 play an important role in the left ventricular hypertrophy of
patients with type 2 diabetes? EBioMedicine. 20:17–18. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shou F, Xu F, Li G, Zhao Z, Mao Y, Yang F,
Wang H and Guo H: RASSF1A promoter methylation is associated with
increased risk of thyroid cancer: A meta-analysis. Onco Targets
Ther. 10:247–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mori T, Sakaue H, Iguchi H, Gomi H, Okada
Y, Takashima Y, Nakamura K, Nakamura T, Yamauchi T, Kubota N, et
al: Role of Krüppel-like factor 15 (KLF15) in transcriptional
regulation of adipogenesis. J Biol Chem. 280:12867–12875. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leenders JJ, Wijnen WJ, van der Made I,
Hiller M, Swinnen M, Vandendriessche T, Chuah M, Pinto YM and
Creemers EE: Repression of cardiac hypertrophy by KLF15: Underlying
mechanisms and therapeutic implications. PLoS One. 7:e367542012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel SK, Wai B, Lang CC, Levin D, Palmer
CNA, Parry HM, Velkoska E, Harrap SB, Srivastava PM and Burrell LM:
Genetic variation in kruppel like factor 15 is associated with left
ventricular hypertrophy in patients with type 2 diabetes: Discovery
and replication cohorts. EBioMedicine. 18:171–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang C and Lin X: Analysis of epidermal
growth factor-induced NF-κB signaling. Methods Mol Biol.
1280:75–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Crofford LJ, Tan B, McCarthy CJ and Hla T:
Involvement of nuclear factor kappa B in the regulation of
cyclooxygenase-2 expression by interleukin-1 in rheumatoid
synoviocytes. Arthritis Rheum. 40:226–236. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cuadrado A, Martín-Moldes Z, Ye J and
Lastres-Becker I: Transcription factors NRF2 and NF-κB are
coordinated effectors of the Rho family, GTP-binding protein RAC1
during inflammation. J Biol Chem. 289:15244–15258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JK, Lee JE, Jung EH, Jung JY, Jung DH,
Ku SK, Cho IJ and Kim SC: Hemistepsin A ameliorates acute
inflammation in macrophages via inhibition of nuclear factor-κB and
activation of nuclear factor erythroid 2-related factor 2. Food
Chem Toxicol. 111:176–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wardyn JD, Ponsford AH and Sanderson CM:
Dissecting molecular cross-talk between Nrf2 and NF-κB response
pathways. Biochem Soc Trans. 43:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Myers PR, Guerra R Jr and Harrison DG:
Release of NO and EDRF from cultured bovine aortic endothelial
cells. Am J Physiol. 256:H1030–H1037. 1989.PubMed/NCBI
|
|
26
|
Nathan C and Xie QW: Nitric oxide
synthases: Roles, tolls, and controls. Cell. 78:915–918. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pang Y, Zheng B, Fan LW, Rhodes PG and Cai
Z: IGF-1 protects oligodendrocyte progenitors against
TNFalpha-induced damage by activation of PI3K/Akt and interruption
of the mitochondrial apoptotic pathway. Glia. 55:1099–1107. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang J, Yang X, Wang H, Zhao B, Wu X, Su
L, Xie S, Wang Y, Li J, Liu J, et al: PKCζ as a promising
therapeutic target for TNFα-induced inflammatory disorders in
chronic cutaneous wounds. Int J Mol Med. 40:1335–1346. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee J, Lee S, Zhang H, Hill MA, Zhang C
and Park Y: Interaction of IL-6 and TNF-α contributes to
endothelial dysfunction in type 2 diabetic mouse hearts. PLoS One.
12:e01871892017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang E, Nayak L and Jain MK: Krüppel-like
factors in endothelial cell biology. Curr Opin Hematol. 24:224–229.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parmar KM, Larman HB, Dai G, Zhang Y, Wang
ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA Jr and
García-Cardeña G: Integration of flow-dependent endothelial
phenotypes by Kruppel-like factor 2. J Clin Invest. 116:49–58.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan Y, Guo Y, Zhang J, Subramaniam M, Song
CZ, Urrutia R and Chen YE: Krüppel-like factor-11, a transcription
factor involved in diabetes mellitus, suppresses endothelial cell
activation via the nuclear factor-κB signaling pathway.
Arterioscler Thromb Vasc Biol. 32:2981–2988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han JM, Li H, Cho MH, Baek SH, Lee CH,
Park HY and Jeong TS: Soy-leaf extract exerts atheroprotective
effects via modulation of krüppel-like factor 2 and adhesion
molecules. Int J Mol Sci. 18:pii: E373. 2017. View Article : Google Scholar
|
|
34
|
Jain MK, Sangwung P and Hamik A:
Regulation of an inflammatory disease: Krüppel-like factors and
atherosclerosis. Arterioscler Thromb Vasc Biol. 34:499–508. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
SenBanerjee S, Lin Z, Atkins GB, Greif DM,
Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, et
al: KLF2 is a novel transcriptional regulator of endothelial
proinflammatory activation. J Exp Med. 199:1305–1315. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bodiga VL, Kudle MR and Bodiga S:
Silencing of PKC-α, TRPC1 or NF-κB expression attenuates
cisplatin-induced ICAM-1 expression and endothelial dysfunction.
Biochem Pharmacol. 98:78–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang X, Guo D, Lin C, Shi Z, Qian R, Fu W,
Liu J, Li X and Fan L: hCLOCK causes Rho-kinase-mediated
endothelial dysfunction and NF-κB-mediated inflammatory responses.
Oxid Med Cell Longev. 2015:6718392015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiao W: Advances in NF-kappaB signaling
transduction and transcription. Cell Mol Immunol. 1:425–435.
2004.PubMed/NCBI
|
|
39
|
Zhou Z, Connell MC and MacEwan DJ:
TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation,
mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial
cells. Cell Signal. 19:1238–1248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fledderus JO, Boon RA, Volger OL, Hurttila
H, Ylä-Herttuala S, Pannekoek H, Levonen AL and Horrevoets AJ: KLF2
primes the antioxidant transcription factor Nrf2 for activation in
endothelial cells. Arterioscler Thromb Vasc Biol. 28:1339–1346.
2008. View Article : Google Scholar : PubMed/NCBI
|
